Essential Site Maintenance: Authorea-powered sites will be updated circa 15:00-17:00 Eastern on Tuesday 5 November.
There should be no interruption to normal services, but please contact us at [email protected] in case you face any issues.

loading page

A Novel Case of Prolonged Ifosfamide Encephalopathy and Long-term Treatment with Methylene Blue: A Case Report & Review of Literature
  • +4
  • Gabriel Chain,
  • Mudit Kalia,
  • Karen Kestenabum,
  • Lara Pappas,
  • Anna Sechser-Perl ,
  • Gadi Abebe Campino,
  • Nibal Zaghloul
Gabriel Chain
Children's Hospital at Saint Peter's University Hospital

Corresponding Author:[email protected]

Author Profile
Mudit Kalia
Children's Hospital at Saint Peter's University Hospital
Author Profile
Karen Kestenabum
Children's Hospital at Saint Peter's University Hospital
Author Profile
Lara Pappas
Children's Hospital at Saint Peter's University Hospital
Author Profile
Anna Sechser-Perl
Children's Hospital at Saint Peter's University Hospital
Author Profile
Gadi Abebe Campino
Sheba Medical Center at Tel Hashomer
Author Profile
Nibal Zaghloul
Children's Hospital at Saint Peter's University Hospital
Author Profile

Abstract

Encephalopathy following Ifosfamide treatment is a well-described phenomenon that is commonly treated with Methylene Blue (MB). The course of encephalopathy and MB therapy has not been described in the literature as lasting longer than 30 days following treatment cessation. We present the case of an 11-year-old female with recurrent episodes of severe somnolence for five months following Ifosfamide-containing chemotherapy for her germ cell tumor. Administration of MB gave immediate but limited response. Our novel case continued to require treatment for 5 months following cessation of therapy. We hypothesize that a genetic component confers increased susceptibility to Ifosfamide-induced encephalopathy.